Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04722887
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2021-01-20
Brief Title:
A Study to Evaluate Safety Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous Human 15 in Participants With Alpha1-Antitrypsin Deficiency
Sponsor:
Organization:
Grifols Therapeutics LLC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
16
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: